William Blair Initiates Alignment Healthcare(ALHC.US) With Buy Rating
Alignment Healthcare Analyst Ratings
Stifel Maintains Alignment Healthcare(ALHC.US) With Buy Rating, Maintains Target Price $14
Stifel Maintains Alignment Healthcare(ALHC.US) With Buy Rating, Raises Target Price to $14
Buy Rating Affirmed for Alignment Healthcare on Strong Growth and Operational Efficiency Prospects Into 2025
Alignment Healthcare Analyst Ratings
Baird Maintains Outperform on Alignment Healthcare, Raises Price Target to $11
Alignment Healthcare Price Target Raised to $10.00/Share From $8.00 by TD Cowen
Piper Sandler Reiterates Overweight on Alignment Healthcare, Raises Price Target to $10
TD Cowen Maintains Alignment Healthcare(ALHC.US) With Buy Rating, Raises Target Price to $10
Piper Sandler Maintains Alignment Healthcare(ALHC.US) With Buy Rating, Raises Target Price to $10
Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), Alignment Healthcare (ALHC) and Akoya Biosciences (AKYA)
Alignment Healthcare Analyst Ratings
Barclays Maintains Underweight on Alignment Healthcare, Raises Price Target to $7
TD Cowen Initiates Alignment Healthcare(ALHC.US) With Buy Rating, Announces Target Price $10
Barclays Maintains Alignment Healthcare(ALHC.US) With Sell Rating, Maintains Target Price $7
Buy Rating Justified: Alignment Healthcare's Strong Q2 Performance and Positive 2025 Outlook
Analysts Offer Insights on Healthcare Companies: Alignment Healthcare (ALHC), Exact Sciences (EXAS) and Fulcrum Therapeutics (FULC)
Analysts Conflicted on These Healthcare Names: Owens & Minor (OMI), Tandem Diabetes Care (TNDM) and Alignment Healthcare (ALHC)
UBS Adjusts Price Target on Alignment Healthcare to $9 From $6.50, Maintains Neutral Rating